Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934221 | 0.94 | TSHR (0.56) | TSHRNPSR1TDP1EZH2L3MBTL1 | |
| SCHEMBL24352530 | 0.91 | TSHR (0.51) | TSHRNPSR1TDP1EZH2L3MBTL1 | |
| SCHEMBL1021679 | 0.89 | TSHR (0.60) | TSHRTDP1EZH2HTT | |
| SCHEMBL1953902 | 0.88 | TSHR (0.57) | TSHRTDP1EZH2THRBGAA | |
| SCHEMBL30409767 | 0.88 | TSHR (0.57) | TSHRTDP1EZH2THRBGAA | |
| SCHEMBL1022247 | 0.88 | TSHR (0.59) | TSHRNPSR1TDP1L3MBTL1GAA | |
| SCHEMBL982145 | 0.88 | TSHR (0.59) | TSHRTDP1EZH2 | |
| SCHEMBL29914212 | 0.88 | TSHR (0.59) | TSHRTDP1EZH2 | |
| SCHEMBL1838093 | 0.86 | TSHR (0.57) | TSHRTDP1 | |
| SCHEMBL1023779 | 0.85 | TSHR (0.56) | TSHRTDP1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753353-B2 | PBX composition | BAE SYSTEMS PLC (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11746069-B2 | PBX composition | BAE SYSTEMS PLC (GB) | 2023-09-05 | — | — | US | disclosed |
| EP-3319928-B1 | PBX COMPOSITION | BAE SYSTEMS PLC (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-11186528-B2 | PBX composition | BAE SYSTEMS PLC (GB) | 2021-11-30 | — | — | US | disclosed |
| US-20210317051-A1 | PBX COMPOSITION | BAE SYSTEMS PLC (GB) | 2021-10-14 | — | — | US | disclosed |
| US-20210300838-A1 | PBX COMPOSITION | BAE SYSTEMS PLC (GB) | 2021-09-30 | — | — | US | disclosed |
| US-10968168-B2 | Isocyanate production method | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20180215678-A1 | PBX COMPOSITION | BAE SYSTEMS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| WO-2017006109-A1 | PBX COMPOSITION | BAE SYSTEMS PLC (GB) | 2017-01-12 | — | — | WO | disclosed |
| EP-3115349-A1 | PBX COMPOSITION | BAE Systems PLC (GB) | 2017-01-11 | — | — | EP | disclosed |
| US-8053595-B2 | Process for producing isocyanates | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-11-08 | — | — | US | disclosed |
| EP-2088137-B1 | A PROCESS FOR PRODUCING ISOCYANATES | ASAHI KASEI CHEMICALS CORP (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | IDH3A, ALKBH3, CPS1 | TSHR 4661/4885NPSR1 4777/4885TDP1 776/4885 |
| US-10968168-B2 | Isocyanate production method | IDH3A, ALKBH3, CPS1 | TSHR 4661/4885NPSR1 4777/4885TDP1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.